Q3 FY2026 EarningsQ3 FY26 results beat consensus on both top and bottom lines: revenue $118.4M vs. $114.5M expected, and gross margin reached 52.8% vs. 52.0% consensus. While GAAP EPS of -$0.56 was slightly lower than the -$0.48 consensus due to higher SG&A, the company raised FY26 revenue guidance to $456M-$457M and reiterated its target for Q4 FY26 Adjusted EBITDA breakeven. DNA Synthesis and Protein Solutions (DSPS) was the primary growth driver, increasing 39% YoY.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Twist Bioscience(TWST) the Revenue is 118.38 M (+23.24%), Beat estimate;the EBIT is -36.28 M (-20.45%), Miss estimate;the EPS is -0.56 (-269.7%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.12B23.24%
0.11B19.25%
+0.00B3.99%
EBITMiss expectations
-0.04B20.45%
-0.03B4.25%
-0.00B16.20%
EPSMiss expectations
-0.56269.70%
-0.482246.06%
-0.078023.64%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf